|Molecular Weight||Approximately 25.3 kDa, a single non-glycosylated polypeptide chain containing 227 amino acids.|
|AA Sequence||YPNASPLLGS SWGGLIHLYT ATARNSYHLQ IHKNGHVDGA PHQTIYSALM IRSEDAGFVV ITGVMSRRYL CMDFRGNIFG SHYFDPENCR FQHQTLENGY DVYHSPQYHF LVSLGRAKRA FLPGMNPPPY SQFLSRRNEI PLIHFNTPIP RRHTRSAEDD SERDPLNVLK PRARMTPAPA SCSQELPSAE DNSPMASDPL GVVRGGRVNT HAGGTGPEGC RPFAKFI|
|Purity||> 95 % by SDS-PAGE and HPLC analyses.|
|Biological Activity||Fully biologically active when compared to standard. The ED50 as determined by thymidine uptake assay using FGF-receptors transfected BaF3 cells is less than 0.5 μg/ml, corresponding to a specific activity of > 2.0 × 103 IU/mg in the presence of 0.3 μg/ml of rMuKlotho and 10 μg/ml of heparin.|
|Physical Appearance||Sterile Filtered White lyophilized (freeze-dried) powder.|
|Formulation||Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.|
|Endotoxin||Less than 1 EU/µg of rHuFGF-23 as determined by LAL method.|
|Reconstitution||We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.|
|Stability & Storage||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
|Usage||This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.|
|Reference||1. Smallwood PM, Munoz-Sanjuan I, Tong P, et al. 1996. Proc Natl Acad Sci U S A. 93:9850-7.|
2. Fu L, John LM, Adams SH, et al. 2004. Endocrinology. 145:2594-603.
3. Kharitonenkov A, Shiyanova TL, Koester A, et al. 2005. J Clin Invest. 115:1627-35.
4. Kurosu H, Kuro OM. 2009. Mol Cell Endocrinol. 299:72-8.
5. Lin BC, Wang M, Blackmore C, et al. 2007. J Biol Chem. 282:27277-84.
6. Kharitonenkov A, Dunbar JD, Bina HA, et al. 2008. J Cell Physiol. 215:1-7.
7. Riminucci M, Collins MT, Fedarko NS, et al. 2003. J Clin Invest. 112:683-92.
8. Shimada T, Hasegawa H, Yamazaki Y, et al. 2004. J Bone Miner Res. 19:429-35.
|Background||Human FGF-23 belongs to the FGF-19 subfamily which has three members FGF-19, 21, 23. All FGF family members are heparin binding growth factors with a core 120 amino acid (a.a.) FGF domain that allows for a common tertiary structure. They are classically considered to be paracrine factors and are known for their roles in tissue patterning and organogenesis during embryogenesis. By contrast, the FGF-19 subfamily has recently been shown to function in an endocrine manner. Members of this subfamily have poor ability of binding to heparin binding site which is a crucial factor in ligand-receptor complex formation. β-Klotho has been identified as co-factor required for FGF-19, 21, 23 signaling. It can obviously increase ligand-receptor affinity. FGF-23 is most highly expressed in bone, from which it circulates through the blood to regulate vitamin D and phosphate metabolism in kidney.|